Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677

Trial Profile

A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mazdutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 07 Jun 2022 Results from NCT03325387 and NCT03928379 analyzing whether LY3305677 improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
  • 25 Aug 2021 According to an Innovent Biologics media release, results will be disclosed at 2021 IDF annual meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top